Navigation Links
Christiana Care Health System Leads National Colorectal Cancer Clinical Trial
Date:3/24/2011

WILMINGTON, Del., March 24, 2011 /PRNewswire-USNewswire/ -- Christiana Care Health System's Helen F. Graham Cancer Center is leading a national clinical trial to determine if Crestor® (Rosuvastatin), a cholesterol-lowering drug, can prevent new colon tumors from forming after colon cancer surgery.

(Logo: http://photos.prnewswire.com/prnh/20090407/DC95299LOGO)

The study seeks to determine if Crestor can stop the growth of tumor cells by blocking some of the enzymes that affect cell growth. The trial will also determine if Crestor can keep new  colon tumors from forming after surgery to remove a patient's initial colon cancer.

The study, entitled, "P-5: Statin Polyp Prevention Trial in Patients with Resected Colon Cancer," is conducted under the auspices of the National Cancer Institute by a network of cancer research professionals, the National Surgical Adjuvant Breast and Bowel Project (NSABP). It takes place at more than 200 medical centers throughout North America.

"Previous epidemiological studies looking back at patient data associated with statin use indicate these drugs lower the risk of colorectal cancer, but the evidence remains controversial," says Bruce Boman, M.D., Ph.D., study protocol chair. "Earlier studies were designed to investigate lipid-lowering or cardiovascular endpoints over the short-term rather than tumor development in the long run."

Dr. Boman is director of Cancer Genetics at the Helen F. Graham Cancer Center's Hereditary Cancer Risk Assessment Program. He is also a scientist at the Center for Translational Cancer Research who investigates how cancer stem cells drive tumor growth.

The study aims to recruit 1,740 patients who have recently been diagnosed with early stage colon cancer and who were not already taking statins for high cholesterol. Patients will be randomly assigned to one of two groups. Each group will take one pill a day for five years. One group will receive Rosuvastatin, the other a placebo.

Investigators also will look at participants with a family history of colorectal cancer and those who take a daily low or high dose of aspirin. Previous studies indicate non-steroidal anti-inflammatory drugs, including aspirin, and statin drugs, like Crestor, work together. Further evidence of this relationship could support reducing doses to improve the risk and benefits of these two types of drugs.

People recently diagnosed with a Stage I or II colon cancer and interested in the study can call the Helen F. Graham Cancer Center's Research Office at 302-623-4550. A list of other participating sites is at the trial website.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Nicholas Petrelli

https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=88807


'/>"/>
SOURCE Christiana Care Health System
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AstraZeneca Donates $1 Million for Christiana Care Health Systems Wilmington Hospital Project
2. Christiana Care Health System Rolls Out Electronic Computerized Provider Order Entry
3. American Imaging Management Promotes Affordability and Choice to Health Care Consumers
4. The Procter & Gamble Company and Teva Pharmaceutical Industries Form Consumer Health Care Partnership
5. Leading Hospitals Committed to Healthcares Adoption of GS1 Standards Use Omnicell Solutions for Supply Chain Management
6. CVS/pharmacy Debuts the "To Your Health" Program in Los Angeles Bringing 240 Free Health Screening Events to the Community
7. New Nationwide Survey Identifies Need for Increased Dialogue Between Gastroesophageal Reflux Disease or Frequent Heartburn Sufferers and Health Care Providers
8. Telome Health, Inc. Launches With Exclusive IP Portfolio
9. Quest Diagnostics Launches National Electronic Health Records Awareness Tour Showcasing Care360 EHR
10. Prognosis Health Information Systems Expands Executive Team
11. International Medical Corps Team in Hardest-Hit Coastal Communities Finds Severe Shortages of Food, Water, Medicines; Acute Need for Mental Health Support
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... DIEGO , Oct. 12, 2017 AVACEN ... recognized the company with their  2017 New Product Innovation Award ... based on extensive primary and secondary medical device market research ... Medical, through its first-to-market OTC, drug-free pain relief product, the ... unique approach to treating fibromyalgia widespread pain. ...
(Date:10/11/2017)... IRVING, Texas , Oct. 11, 2017  Caris ... science focused on fulfilling the promise of precision medicine, ... Institute has joined Caris, Precision Oncology Alliance™ (POA) as ... leading cancer centers, the St. Jude Crosson Cancer Institute ... to advance the use of tumor profiling, making cancer ...
(Date:10/10/2017)... EXTON, Pa. , Oct. 10, 2017   ... leader in innovative solutions for injectable drug administration, today ... of West,s ID Adapter for improving the intradermal administration ... the Fourth Skin Vaccination Summit in May 2017 by ... Team Lead, Polio Department, World Health Organization (WHO), and ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers care ... have a waiver for care if the client has a cognitive impairment diagnosis. ... for care, is often waived, so the benefits from their insurance start immediately,” said ...
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released a ... books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture of ... have tossed it off as mere rubbish, but Yisrayl Hawkins says that is because ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history of ... Brink” is the creation of published author, William Nowers. Captain Nowers and his ... veteran, he spent thirty years in the Navy. Following his career as a ...
(Date:10/12/2017)... Wis. (PRWEB) , ... October 12, 2017 , ... ... standard products to meet the demand of today’s consumer and regulatory authorities worldwide. ... of probiotic experts and tested to meet the highest standard. , These ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: , ... to enable prevention of a major side effect of chemotherapy in children. Cisplatin ... patients. For cisplatin, hearing loss is FDA listed on-label as a dose limiting ...
Breaking Medicine News(10 mins):